No Data
No Data
Revance to Participate in Upcoming Investor Conferences
Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will be participating in the following investor conferences. William Blair 44th Annual Growth Stock Conference Chief Financial Officer Tobin
Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
Revance Therapeutics Is Maintained at Neutral by Goldman Sachs
Revance Therapeutics Is Maintained at Neutral by Goldman Sachs
Express News | Goldman Sachs Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8
Barclays Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
Revance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ...
No Data